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Introduction
Clostridioides difficile formerly known as Clostridium difficile is an opportunistic
pathogen that is scientifically and medically relevant due to its ability to cause infectious disease
such as infectious diarrhea or colitis [1,2]. Globally, C. difficile is among the leading cause of
hospital-acquired infectious diarrhea and is associated with significant morbidity and mortality
with an estimated half a million infections per year [21, 22]. It is most often found within the
long-term healthcare setting due to the abundance of susceptible hosts [3]. A susceptible host is a
patient that has a weakened immune system or has decreased or eliminated their normal
intestinal flora in response to antibiotic therapy [4]. Due to antibiotic therapy, a patient’s normal
flora within the intestines is suppressed or removed, producing an unintended optimal growth
environment for C. difficile [5].
This gram-positive, endospore-forming, obligate anaerobe bacterium has a variety of
virulence factors such as resilience to disinfectants, antibiotics, and stomach pH, which allows it
to thrive in a healthcare setting [6,7]. As a result of these characteristics in combination with a
compromised gut biota in a susceptible host, C. difficile can then produce transmissible and
dormant endospores that are able to withstand harsh chemical and physical environments as well
as survive for long periods of time [8]. These spores can travel the gastrointestinal tract, where
the optimal environmental factors will trigger germination and permit the growth of vegetative
cells [7]. For transmission, the spores are excreted from the body and into the feces. Once there,
these spores are unknowingly transmitted to other surfaces until they are swallowed by another
person, which can cause an infection in a new host [8].
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This model organism is also able to produce two toxins, enterotoxin A and cytotoxin B,
which are responsible for the disease symptoms with the timing of their release from infecting
cells paralleling sporulation [9,10]. These two toxins are important for C. difficile as they play an
important role in the sporulation and infection process. There are methods to treat this infection
of the gastrointestinal tract such as antibiotics or a fecal transplantation. The patient would need
to stop the antibiotic treatment they were on previously and start an entirely new one, but this
method is not always effective. In the case of the fecal transplantation, a donor’s fecal matter is
used to reestablish the normal intestinal microbiome in the patient. Neither treatment is
completely effective, however. Treatment failures and the recurrence of C. difficile infections
have pushed the scientific community to search for potential treatment options [21].

Figure 1. C. difficile infection pathway [23]

My research efforts were directed toward the structure and functionality of a protein,
designated SpoIIE [11], which previously has been shown to regulate C. difficile peptide
utilization in addition to sporulation and toxin release. The SpoIIE protein is found in all spore5

forming gram-positive bacteria and is a crucial component in activation of transcription factors
and septum formation thus affecting the regulation and timing of spore development [11,12]. A
truncated form of the SpoIIE protein named SpoIIE∆TM was used in an effort to determine the
structure of an important but uncharacterized linker domain of the protein. If the structure and
specific function of this region were to be discovered, it would provide valuable information
regarding the complex reaction cycle of SpoIIE and its relevant virulence factors.
To understand more about the structure and function of the protein, there were two
components of my research. To begin, The SpoIIE∆TM protein segment was modelled using ab
initio modeling systems computationally. The benefit of using this type of modeling is it can
predict the structure of a protein without using any previously known structures [13]. This is
useful for proteins that are newly discovered and do not have many structures in the Protein Data
Bank (PDB) such as the currently unmodeled linker region of this protein [13]. Multiple
programs were used to provide a variety of structures of SpoIIE∆TM to compare. Based on the
models provided, ideal structures would show an exposed region that of SpoIIE that might define
the protein-protein interaction domain of SpoIIE. This first component was completed providing
multiple viable structures created from modeling programs such as Robetta [14] and I-Tasser
[15]. The structure(s) are preeminent in the second component of research. Further discussion
about modeling programs will be completed in Results and Discussion section.
In contrast to the purely electronically acquired data, the second component was in vitro
and provided physical data. The protein SpoIIE is known to regulate peptide transport within C.
difficile which is essential for cell function and plays a vital role in the sporulation process. To
understand this relationship and determine which specific area of the SpoIIE protein is
responsible for regulating peptide transport, site-directed mutants in SpoIIE were analyzed. If the
6

peptide transport process becomes inactive after mutagenesis, it can be concluded which segment
is responsible for regulating the transport process. Specifically for in vitro experimentation
methods, two strains of the SpoIIE gene named pUA626 and pUA629 were used throughout all
reactions. Their sequencing and annotated plasmid map can be show in figure 2 and 3. In
addition, models completed previously and ab initio data from completed previous threading
results from the Ivey lab will be compared to collect substantial evidence supporting or denying
the various segments tested.

Figure 2. pUA626 annotated plasmid map generated by the Ivey Lab
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Figure 3. pUA629 annotated plasmid map generated by the Ivey lab

This research project used preliminary data gathered by previous students within the Ivey
lab to guide this thesis project. This data provides multiple structures created using threading
through a multitude of programs as well as experimental methods that were not able to be
completed due to the COVID-19 pandemic. This project was a continuation and extension of this
research idea started in the Ivey lab. It was anticipated some of the experimental methods and/or
procedures would need to be altered to comply with the regulations or problems that occurred as
this research took place. Described below were experimental designs and methods in compliance
with the respective COVID-19 regulations at the respective time.
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Materials and Methods
Computational Modeling
For this component of my research, primarily two ab initio protein modelling software
programs, I-Tasser and Robetta, were accessed and used through free online servers to develop
models of the C. difficile SpoIIE. The first 100 amino acids of hydrophobic residues were deleted
from the SpoIIE fasta file to create a final sequence of 471 amino acids. I-Tasser did require the
user to make an account therefore that was completed. The sequence which can be observed in
figure 4 was then uploaded into each respective program in fasta format. Once the models were
produced, comparisons between the various models for each program were made to determine
which protein model was thought to be most accurate in terms of the unknown transmembrane
region.

Figure 4. SpoIIE Sequence with the first 100 Amino Acids removed as shown in a
fasta format.

Polymerase Chain Reaction (PCR)
Multiple polymerase chain reaction (PCR) cycles were completed to amplify targeted
genomic DNA sequences, such as pUA626 and pUA629, for subsequent recombinant
techniques. Primers were used as a complementary single-stranded DNA to our targeted
sequence, SpoIIE, to initiate replication with DNA polymerase. Table 1 shows the primers used
9

in the PCR cycles, their sequences, and the source. The master mix used was GoTaq Long PCR
Master Mix by Promega Corporation. This contains the higher performance GoTaq Hot Start
Polymerase for longer DNA amplification. Each PCR reaction for initial DNA amplification was
performed in 49.5 µL, comprised of 25 µL GoTaq Long PCR 2x Master Mix, 22.5 µL of
deionized or nuclease free water, 1 µL of pUA626 and pUA629 respectively, 0.5 µL Eurofin 1/2
primer, and 0.5 µL Eurofin 2/2 primer to create a 49.5-50 µL sample in a 0.2 mL PCR tube. The
Thermal cycler (MWG-Biotech) was used to complete PCR amplification, and the reaction
conditions were 95°C for 2 min, 30 cycles of 92°C for 30s, 45°C for 30s, 65°C for 6 min, and
extension at 72°C for 10 min. These conditions were determined from previous experiments.
Verification of PCR amplification was completed through gel electrophoresis.
Table 1. Primers used for PCR
Primers

Sequence (5’→ 3’)

Source

Spo2e TMF

CCAGAGCGATTATTTAATAAG

Eurofins

CTCGAGCTCGGATCCCCATCG

Eurofins

1/2
Spo2e TMR
2/2

Gel Electrophoresis
Many gels were completed to examine and distinguish different samples of DNA based
on their size and length traveled through the gel. Quantity of DNA was observed and used as
confirmation of success for completed procedures prior to moving to the next step by comparing
the brightness of each band as a brighter band suggests increased amounts of DNA. Two
different types of gels were used throughout my research processes, but the protocol was the
same fundamentally for each. To make the first gel, 160 mg agarose was added to 20 mL of TAE
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buffer from a lab stock in a flask and then heated until bubbles formed. After letting cool, 2 µL
of EZ-Vision Bluelight DNA Dye by VWR Chemicals LLC was added to the flask. The mixture
was then poured into gel mold with variable comb size needed and allowed to cool for 15
minutes. Once DNA molecular weight marker and samples were loaded into the gel, it was
allowed to run at 100V for 20 min using the Embitech Run One Electrophoresis Cell. The second
type of gel had similar protocol, however, the mixture contained 40 mL of TAE, 280 mg of
agarose, and 4 µL of EZ-Vision Bluelight DNA Dye. The gel was allowed to run at 60V for 40
min using the EC Apparatus Corporation Gel Electrophoresis. The DNA marker mix used
consisted of 4 µL 1 Kb DNA marker, 6 µL deionized water, and 1 µL 2x concentration dye for
all gels completed. The amount of products loaded into the gel varied throughout my research
with specific measurements provided for each respective process, however, the concentration of
2x dye were always added to the products. Ideally, the wells loaded had 10 µL, however,
procedures completed did not produce a full 10 µL therefore less was loaded into the gel well
and allowed to run.
Site-Directed Mutagenesis
Site-directed mutagenesis was completed in efforts to remove the transmembrane anchor
region from the SpoIIE gene of the strains pUA626 and pUA629. To complete these procedures,
manufacturer’s instructions were followed of the Q5 Site-Directed Mutagenesis Protocol by New
England Biolabs (NEB) located on the website protocols.io for the kinase, ligase, and DpnI
(KLD) Treatment. Additionally, the manufacturer’s instructions were followed for the
transformation process as well but with an adjustment to the amount of PCR product and
incubation time used in the process. This protocol was not followed for the PCR reaction as
previous protocol yielded positive results; therefore, the exact same protocol was followed when
11

repeated. PCR reaction was completed as stated in Polymerase Chain Reaction (PCR) section
and the products produced from it were used in the subsequent site-directed mutagenesis
procedures.
DpnI Digestion
The purpose of the DpnI digestion following a PCR of plasmids was to destroy all
parental template plasmid DNA due to DpnI only digesting the methylated portions of DNA.
Because my PCR product because is unmethylated, DpnI will select for the mutated plasmids by
only removing methylated plasmid. Protocol for this procedure was the addition of 1 µL of DpnI
to PCR products and subsequent incubation at 37°C for 1 hour.
Purification
Following DpnI digestion, purification was immediately followed. Manufacturer’s
instructions of the MicroElute DNA Cleanup kit (Omega Bio-tek). Steps 1, 3, and 14 from the
manufacturer’s instructions were range values therefore specification used in my procedure will
be provided. For step 1, about 40 µL was measured for each tube; for step 3, 120 µL was added
to the PCR tubes; lastly, for step 14, 10 µL was added. All other steps were followed accordingly
to manufacturer’s instructions
Kinase and Ligase Reaction
The purpose of the Kinase and Ligase reaction was to allow efficient phosphorylation,
intramolecular ligation and circularization, and template removal. This procedure uses a KLD
Enzyme mix which is a blend of Kinase, Ligase, and DpnI enzymes and an enzyme buffer. Due
to this mixture, this step is the most crucial and sensitive step within the site-directed
mutagenesis process. To begin, 5 µL of 2x KLD Reaction Buffer, 1 µL KLD Enzyme mix, and 4
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µL of PCR product that was prepared in earlier section were added into a PCR tube. To mix
properly and gently, the reagents were pipetted up and down. The mixed solution was then
incubated for 5 minutes at room temperature and then the transformation procedure according to
manufacturer’s instructions with slight variation was completed. An additional identical cycle of
kinase and ligase reaction was performed with the only exception being the sample was
incubated at 15°C overnight in the Biotech Thermal cycler. Two cycles were completed due to
time constraints and to increase the likelihood of colony formation within the plating step which
will be discussed.
Transformation
As stated earlier, the transformation process used the manufacturer’s protocol of the Q5
Site-Directed Mutagenesis by New England Biolabs (NEB) located on the protocols.io website.
NEB C2987 chemically competent E. coli cells were transformed so that my targeted plasmid
sequence of each pUA626 and pUA629 with the transmembrane region presumably deleted was
inserted into the cells. The only difference noted in procedure was that 4 µL of KLD product was
used instead of the 5 µL that is called for in the protocol. Each cycle of KLD products underwent
transformation at separate times but was completed as stated.
Plating
For the plating process, the plates used were Luria-Bertani (LB) medium with antibiotic
ampicillin added (LB-amp) that were created according to the Biotechnology Explorer Microbial
Culturing Kit Preparation of LB-Ampicillin Agar protocol. The plates had a concentration of 10
mg/ml ampicillin to LB medium as outlined in the protocol and were stored at 4°C until used.
Transformed E. coli cells were then pipetted onto the plate surface and then streaked with a
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sterile loop by an open flame. The set of plates were then incubated overnight at 37°C. Table 2
shows the cycle, plasmid, as well as amount pipetted onto the plates. Cycle two used a control of
pUC19 Control DNA by New England Biolabs (NEB) to ensure the plates were viable and could
allow for colonization of the E. coli. 1 µL of pUC19 was added to the tube of competent E. coli
cells following protocol and later the transformed cells were plated in the process identical to my
samples.
Table 2. Plating Protocol
Cycle

1

2

Plasmid

Amount (µL)

pUA626

10

pUA626

100

pUA629

10

pUA629

100

Control

100

pUA626

10

pUA626

100

pUA629

10

pUA629

100

Colony Selection and Broth Cultures
After incubation of transformed E. coli cells on LB-ampicillin plates and colony
formation, colonies were picked and inoculated into liquid broth for further growth. Plates
resulted in two viable colonies for pUA626 and four viable colonies for pUA629. Sterile wooden
applicator sticks were used to pick a single colony by pressing gently to it and then swishing the
stick into the liquid broth tube. The broth is made of 33 µL of carbenicillin and 33 mL of
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laboratory LB stock broth. About 4 mL of this broth mixture was deposited in a total of 6 tubes
and each held their respective colony picking. These inoculated tubes were then shaken
overnight at 37°C. Carbenicillin was used over ampicillin due to the more difficulty to build up a
resistance to carbenicillin.
Viogene Plasmid DNA Extraction
Following incubation, about 1.6 mL of broth culture and was processed using
manufacturer’s protocol within the mini plus plasmid DNA extraction system (Viogene).
Products created from this procedure were then separated by agarose gel electrophoresis to
confirm the viability of the mutant plasmids. The new mutant plasmids should be smaller than
the original plasmids due to the deleted region allowing the DNA to run faster in the gel and thus
travel farther.
Restriction Endonuclease Digest
Two different digests were completed to observe the weight and brightness of mutants on
a gel. The first digest was using the restriction enzyme EcoRV. The locations of this restriction
enzyme for each mutant can be observed on the original strain plasmid map shown in figures 2
and 3. The original pUA626 and pUA629 were included in this digest and gel because we
wanted to observe the difference between my mutant plasmids and the original strains. Ideally,
the mutants should be smaller in size due to the portion deleted, therefore they should run faster
on the gel showcasing this smaller size. Comparison between the original strains and mutants
offers some idea if procedures were a success without sequencing being completed yet to give
full confirmation. For the EcoRV digest, 5 µL of plasmids, both mutant and original, were added
to 3 µL of deionized water, 1 µL of EcoRV, and 1 µL of NEB 3 Buffer into a PCR tube. The

15

PCR tubes were then incubated at 37°C for 30 minutes. A gel was then performed using the
second style of gel. All products from incubation were used when loading the gel therefore 1 µL
of 2X dye was added to about 10 µL of product. Marker was prepared and all products were
loaded into gel and ran at 60V for 40 minutes. The second digest performed included the
restriction enzyme PvuII with the same protocol as for EcoRV.
Sequencing
Sequencing is to be completed by Plasmidsaurus.com which is said to provide complete,
accurate, and full-length plasmid sequencing. Information from the “Prep&Ship” tab located on
their website was used to determine what concentration our mutant samples needed to be at.
Based on our mutant plasmid DNA length, the concentration of our samples needs to be at least
10 µL normalized to 30ng/µL. Concentration of samples were measured with Qubit
quantification, reagents, and buffer. First product concentration was not high enough, therefore it
was decided to grow a new culture overnight to achieve more sample product. It was decided
that due to limited time, mutation samples 1 and 2 of pUA 626 would be grown first as they were
the most promising out of all mutated samples. To grow new cultures, 50 µL of ampicillin and
100 µL of previously grown cultures were added to liquid broth and incubated with shaking
overnight at 37°C. Next, the Viogene plasmid DNA extraction was completed for 5 samples of
each mutant in hopes of having plenty of product to achieve a high concentration. To help
achieve a high concentration, centrifugal filter Centricon-10 was used in conjunction with a
Heraeus centrifuge. Concentrations of this product were then calculated using the Qubit
manufacturer protocol and device. Due to issues with achieving the correct concentration of
product, we were unable to go further past this step in this process for sequencing at the current
moment. We are hopeful to send off results and achieve sequencing maps prior to the end of the
16

semester in order for accurate conclusions to be reached. Determinations for what is next in the
Ivey lab can then be concluded.
Results and Discussion
The goal of this thesis project was to model the unknown transmembrane linker region of
SpoIIE and compare this model to data gathered from in vitro experiments to determine if the
model is accurate. The transmembrane linker region has not been crystalized meaning the
structure is still unknown in current scientific literature. If positive results were yielded from this
project, possible protein models would be identified for the SpoIIE gene of C. difficile.
Furthermore, if sequencing results show that our mutant strain effectively deleted the
transmembrane region, research efforts in the Ivey lab can be geared toward crystallization.
Ab Initio Modeling
As stated previously, two ab initio protein modeling software systems were used. Each
produced variable models, however, the primary goal of using two different systems was to
compare the models against one another to look for key similarities or differences. Figures 5 and
6 show two models produced by Robetta that we believe are most accurate due to the higher
order of its folding as they have more tertiary structures, specifically alpha helices, than other
models produced.
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Figure 5 (left) and Figure 6 (right). Robetta models of C. difficile SpoIIE fasta format.

The key areas of interest of these models are the dark blue and purple regions which we
believe represent the transmembrane region of SpoIIE. The linker region needs to be accessible
as it has contact with dimers; The purple alpha helices of these two models show a conformation
synonymous with its known needs and functions. The other colored structures are the regulatory
regions of SpoIIE and are well known and studied throughout scientific literature. Our focus is
on the transmembrane linker region which we believe to be the purple and dark blue alpha
helices and is located away from the regulatory regions. Using in vitro lab experiments outlined
previously, we believe we removed the transmembrane region from SpoIIE.
Secondly, the program I-Tasser was used to produce protein models and compare against
models created by Robetta. Figures 7 and 8 show the models we believed are most likely
accurate. It is important to note that comparison of the two program models were done with both
18

showing the believed transmembrane region located away from the regulatory regions. While the
folding of the dark blue region in model 5 (Figure 7) is different compared to models 1 and 5
(figures 5 and 6), it is important to observe the protein structure conformation of alpha helices is
similar. Model 2 of I-Tasser (figure 8) is a great example to show the distance between the
regulatory regions of the SpoIIE protein and the believed transmembrane linker region.
Comparison of models between the two provides evidence of similar structures by means of
conformation and level of folding.

Figure 7 (left) and Figure 8 (right). I-Tasser model of C. difficile SpoIIE fasta format with the first 100
amino acids deleted.

In Vitro Experiements
Essentially, three cycles of the procedures were completed until viable results were
formed. However, two specific procedures were not used in the final successful procedures
19

because the results from their specific protocols were deemed unsuccessful. It is important to
note that efforts were made to complete these procedures to ensure that the results we received
did exhaust all options. Within the first cycle, DpnI digestion was completed but it did not
provide positive results therefore it was no longer used in subsequent cycles. Additionally, the
purification procedure was completed in the first and second cycle attempts with no successful
results and thus it was not used in the third cycle attempt.
To begin the in vitro portion of this project, difficulties occurred with the initial PCR
attempts as they proved to be unsuccessful when
attempting to confirm DNA amplification
through gel electrophoresis. Various master
mixes and primers were tested until a positive
result was yielded (Figure 9). It was determined
that a new master mix and new enzymes were
needed as the previous ones were not successful
at amplifying the original strains of DNA of
pUA626 and pUA629. By having new master
Figure 9. Gel electrophoresis confirming
amplification of DNA using new master
mix and new primers. From left to right
samples are as follows: marker, original
pUA626, and original pUA 629.

mixes and new enzymes, we were able to
confirm through gel electrophoresis that we
started the project with viable DNA; Thus, if

products were shown to be unyielding of results, we would know it would be the subsequent
process as the culprit instead of the original DNA strains. Once all reagents of PCR were
confirmed to be in good working condition, we were able to continue with the procedures. Prior
to beginning the third cycle of procedures, PCR was
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completed again a gel of the
PCR results was completed to ensure
viability of DNA and proper
amplification had occurred due to
negative results of the second cycle of
procedures (figure 10). By the third
cycle of procedures, we were able to
receive viable results.

Figure 10. Gel result of PCR prior to final cycle of
procedures. Amplification of plasmids can be observed.
From left to right samples are as follows: marker, original
pUA626, and original pUA 629.

Plating and Culture
Using protocol stated for plating and broth cultures, mutant strains of pUA626 and
pUA629 were created through the removal of the transmembrane linker region. Competent E.
coli cells with our mutant plasmid inserted into it were spread across LB-ampicillin plates with
the most successful being the spread of 100 µL. Mutant 626 had growth of a total of two colonies
that were picked (figure 11). It is important to note, two Kinase and Ligase reactions were
completed to increase the likelihood of possible colony growths, however, the two colonies of
626 strain were picked from the second kinase and ligase reaction. Mutant 629 had growth of
four colonies that were picked (figure 12). Lastly, a control was completed to ensure the plates
were optimal for cell growth (figure 13).
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Figure 12. Result of mutant 629 colony
growth on LB-ampicillin plate.

Figure 11. Result of mutant 626 colony
growth on LB-ampicillin plate.

Figure 13. Positive result of control pUC19
colony growth on LB-ampicillin plate.
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Once colonies were picked from each mutant plate, they were inoculated into liquid broth (figure
14). As stated previously, mutant 626 had 2 samples and mutant 629 had 4 samples. Cloudiness
of liquid broth samples show growth of cells and indicate viability of cells.

Figure 14. Results of colony inoculation into liquid broth and
carbenicillin solution.
Restriction Enzyme Digests
We believe we have successfully removed the transmembrane region of pua626 and 629
which can be shown on the models if proven correct. However, PCR can introduce unplanned
changes within the plasmid; therefore, restriction enzyme digestions and subsequent gels as well
as sequencing can be completed to verify our mutants are missing the transmembrane linker
region. Gel imaging of the restriction enzyme digest can broadly confirm that our mutants have
the same pattern we'd expect, however, sequencing would need to be done to have complete
confirmation that the correct region was deleted (Figure 15 and Figure 16). Additionally, it needs
to be noted that the EcoRV gel's marker malfunctioned therefore it is not visible so we cannot
23

determine the exact size of the samples; however, generally we can confirm that our mutant
samples are smaller than the original plasmids which is what we would want to se. Logically, it
makes sense for our mutants to be smaller as they are missing an entire region of DNA. The
restriction enzyme PvuII cuts the plasmid DNA in two separate places creating two separate
DNA fragments. This causes there to be two bands within the gel for each sample indicating
positive results for each mutant. Based on size and brightness of mutants as compared to the
original plasmids, the EcoRV gel and PvuII gel shows broad confirmation that a deletion did
occur.

Figure 16. Gel results of PvuII digest of
mutant and original plasmids showing two
separate bands for mutant strains indicating
positive result. From left to right samples are
original pUA626, 626-1, 626-2, original pUA
692, 629-1, 629-2, 629-3, 629-4, and marker.

Figure 15. Gel results of EcoRV digest of mutant
and original plasmids with mutants being smaller
than originals indicating positive result. From left to
right samples are original pUA626, 626-1, 626-2,
original pUA 692, 629-1, 629-2, 629-3, and 629-4.
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Sequencing
The digests indicated the mutants were smaller than original plasmids which confirmed
the need for sequencing to determine with confidence which region was deleted. Problems arose
with the sequencing preparation unfortunately so at this time, we currently do not have the
mutation sequencing nor the plasmid maps which would be similar to figures 1 and 2. For the
plasmid preparations, samples need to be at a certain concentration for Plasmidsaurus to
sequence them. Procedures completed to achieve the concentration were unsuccessful even after
further concentration efforts. Additionally, the plasmids only ship out once a week and we were
unable to meet the deadline in order to receive the sequencing results in a sufficient amount of
time. We do plan to sequence our mutants to reach conclusions based on our efforts this far.
The results of the sequencing will either confirm that we have made a mutant of SpoIIE
without the transmembrane region, or that all of our research efforts for this project were unable
to confirm the deletion of the transmembrane region and thus unable to confirm any models. If
sequencing confirms our mutants, the Ivey lab will have a new strain to use in future experiments
and endeavors.
Future Directions
Further directions for this research project are subjective to what I am able to accomplish
with my remaining time within the lab. It is expected that I will complete sequencing as well as
possibly do fluorescence assays, however, results of these procedures may not be presented for
this thesis due to time constraints. Possible future directions include but are not limited to
fluorescence assays, if I am unable to complete them, as well as immunoprecipitation and
western blotting for these specific mutants if they are confirmed to have correctly deleted the
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linker region. Fluorescence assays can be completed to assess the protein functionality and
determine the peptide transport gene expression level. Thus, the protein functionality could be
discovered to correspond to a specific region and intramolecular contact sites may be
determined. Immunoprecipitation can be completed to observe the intermolecular interactions of
wild-type and the mutated SpoIIE∆TM. Western blotting will follow IP to verify the identities of
binding partners used in the IP process and provide further information regarding our threedimensional protein models. It is hopeful that the mutants created for this thesis will yield
positive results and will then become a new strain within the Ivey lab for future endeavors to be
completed with. Ultimately, the work and data presented in this thesis may contribute to future
research projects within the Ivey lab that can be done by incoming undergraduate students.
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